T he renin angiotensin system has been strongly implicated in hypertension and its complications. Importantly, it has been suggested that the mechanisms by which angiotensin II (AngII) elevates blood pressure and enhances end-organ damage may be distinct. 1 Vascular remodeling associated with hypertension has been strongly implicated in end-organ damage and associated with poor cardiovascular outcomes. 2,3 The remodeling predisposes to end-organ damage and pharmacological intervention in vascular remodeling should have special clinical efficacy for prevention of hypertensive complications. 2,3 However, the exact signal transduction cascade by which AngII mediates vascular remodeling such as medial hypertrophy and perivascular fibrosis remains insufficiently understood. Therefore, the rationale of the present study is to explore the signal transduction mechanism of AngII required for the initiation of vascular remodeling but not hypertension and to test its functional relevance to seek a novel treatment for hypertensive complications.
. Effects of epidermal growth factor receptor (EGFR) inhibitor, erlotinib, on cardiovascular remodeling induced by angiotensin II (AngII). C57Bl/6 mice were infused with saline (n=8) for 2 weeks, or AngII (1 μg/kg per minute) for 2 weeks with (n=8) or without (n=8) treatment of erlotinib (10 mg/kg per day IP injection). Hearts and kidneys were stained with Sirius red and aortas were stained with Masson trichrome (mean±SEM). A, Representative staining (×200) is presented. B, Quantification of medial area to internal arterial area of the coronary and renal arteries and quantification of perivascular fibrosis area to vascular area of these arteries. C, Quantification of medial thickness of the thoracic aorta. D, Heart weight (HW) body weight (BW) ratio. E, Mean arterial pressure (MAP) was evaluated by telemetry. F, Heart sections were immunostained with antibodies as indicated (n=4). Antibodies against Lys-Asp-Glu-Leu (KDEL) and CCAAT/enhancer-binding protein homologous protein (CHOP) were used to assess endoplasmic reticulum stress. Antibody against nitrotyrosine (nTyr) was used to assess oxidative stress. *P<0.05 compared with control saline infusion. †P<0.05 compared with AngII infusion.
by guest on August 30, 2017 http://hyper.ahajournals.org/ Downloaded from neointima after angioplasty, and dominant-negative ADAM17 gene transfer prevents the EGFR activation and neointimal hyperplasia. 8 Others have shown that the EGFR activation mediates AngII-induced reactive oxygen species generation in VSMCs, 9 and EGFR antisense 10 or ADAM17 interfering RNA 11 can suppress AngII-induced cardiac hypertrophy. Data from mice having mutant EGFR further support the role of EGFR in AngII-associated cardiac remodeling. 12 However, whether an EGFR inhibitor such as erlotinib used for human cancer treatments 13 has therapeutic potential against hypertensive vascular remodeling remains unclear.
Literature increasingly suggests that prolonged ER stress and the subsequent unfolded protein response likely contribute to the development and progression of cardiovascular diseases such as heart failure and atherosclerosis. 14, 15 Although the downstream consequences of prolonged ER stress generally involve unfolded protein response-specific gene programs, 16 ER stress seems critical for enhancement of reactive oxygen species in many organ and cell systems including VSMCs. 14, 17 AngII has been shown to enhance ER stress in vitro and in vivo, 18, 19 potentially mediating enhancement of oxidative stress and subsequent target organ damage. Supplementation of ER chaperone 78-kDa glucose-regulated protein into the subfornical organ of the brain has been demonstrated to be effective in attenuating AngII-induced ER stress and hypertension. 20 In addition, recent evidence suggests a link between EGFR and ER stress. 21 Taking the above information together, we have tested our hypothesis that activation of EGFR and ER stress are critical components required for vascular remodeling but not hypertension induced by AngII using mice treated with an EGFR inhibitor or ER stress inhibitor. Our findings support this hypothesis and further demonstrate a novel concept of ADAM17 induction by EGFR via ER stress, potentially amplifying hypertensive end-organ damage mediated by the renin angiotensin system.
Methods
Extended Methods are provided in the online-only Data Supplement.
Results
To test for the role of EGFR activation in AngII-induced vascular remodeling, AngII-infused mice were treated with or without an EGFR kinase inhibitor, erlotinib. Two weeks of AngII infusion in control mice caused vascular medial hypertrophy in coronary arteries, renal arteries, and aortas that was markedly (but not completely) prevented in mice treated with erlotinib. Perivascular fibrosis in coronary and renal arteries induced by AngII infusion was partially or completely prevented in erlotinib-treated mice, respectively ( Figure 1A -1C). AngII-induced cardiac hypertrophy assessed by heart weight:body weight ratio ( Figure 1D ) and echocardiogram (Table S1 in the online-only Data Supplement) was partially or completely attenuated in erlotinib-treated mice, respectively. In contrast, hypertension was induced in both nontreated and erlotinib-treated mouse groups infused with AngII ( Figure 1E ; Table S2 ). In addition, body weight and heart rate remained the same among the 3 animal groups (Table S2 ).
The AngII-induced vascular remodeling in control mice was associated with vascular EGFR activation, ER stress, and oxidative stress assessed by immunohistochemistry. These AngII responses were markedly attenuated in mice treated with erlotinib ( Figure 1F ; Figure S1 ). We were unable to assess active EGFR in the myocyte area of the heart because of lack of any significant staining in response to AngII infusion. ADAM17 expression was barely detectable in heart tissue but was significantly induced on AngII infusion in the coronary arteries. No such induction was seen in mice treated with erlotinib. Erlotinib also inhibited EGFR activation, 78-kDa glucose-regulated protein induction, ADAM17 protein induction, and promoter activation in VSMCs stimulated with AngII ( Figure 2 ; Figure S2A ).
To test for the role of ER stress in AngII-induced vascular remodeling, AngII-infused mice were treated with a chemical ER chaperone, 4-phenylbutyrate (PBA). PBA prevented AngII-induced vascular hypertrophy, perivascular fibrosis, and cardiac hypertrophy markedly (but not fully except in renal arterial fibrosis) but not hypertension (Figure 3 ; Tables S1 and S2). In addition, AngII-induced vascular ADAM17 induction, EGFR activation, and enhancement of ER/oxidative stress were prevented by PBA treatment ( Figure S3 ). PBA inhibited AngII-induced ADAM17 protein expression and promoter activity in cultured VSMCs ( Figure 4A ; Figure  S2B ). Gene-transfer of ER chaperone, 78-kDa glucose-regulated protein, inhibited AngII-induced ADAM17 protein Figure 4B ). PBA also attenuated AngII-induced EGFR activation in VSMCs ( Figure S2C )
Discussion
The major finding of the present study is that AngII-induced vascular hypertrophy and perivascular fibrosis were attenuated in mice treated with inhibitors of EGFR and ER stress, and that these protective effects were independent of hypertension. The suppression of AngII-induced vascular hypertrophy in erlotinib-treated mice is in line with our past in vitro observations that genetic ADAM17 silencing or inhibition of EGFR transactivation prevented the hypertrophic responses in cultured VSMCs. 5, 7 Moreover, mice with sm22α-promoter-dependent EGFR silencing have less baseline arterial wall to lumen ratio while blood pressure increases to the same extent as wild type on acute AngII infusion, 22 thus supporting the role of EGFR in vascular hypertrophy.
It is intriguing that pharmacological EGFR inhibition also prevented perivascular fibrosis induced by AngII, as low expression of ADAM17 under normal conditions and enhanced expression in areas of interstitial fibrosis damaged human kidneys have been reported. 23 In addition, AngIIinduced renal interstitial fibrosis can be inhibited in proximal tubule-specific EGFR null mice or with erlotinib treatment, 24 and cardiac-specific heparin-binding EGF-like growth factor transgenic mice develop cardiac fibrosis. 25 In our control model of 2-week AngII infusion, interstitial fibrosis within the heart was too marginal to be quantitatively evaluated. However, it is likely that the paracrine production of heparinbinding EGF-like growth factor and activation of EGFR via activation of ADAM17 in VSMCs, as well as other cell types, may be critical for the development of overall tissue fibrosis associated with hypertension.
The present study demonstrating predominantly vascular ADAM17 induction and EGFR activation suggests a vascular contribution to cardiac hypertrophy via EGFR transactivation induced by AngII. It should be noted that vascular smooth muscle (but not cardiac myocyte)-targeted G q inhibition attenuates cardiac hypertrophy in AngII-infused mice. 26 However, cardiac myocyte-targeted expression of dominantnegative EGFR inhibited cardiac hypertrophy induced by AngII. 12 Cardiac-specific deletion of an ER stress sensor, double stranded RNA-activated protein kinase R-like ER kinase exacerbates pressure overload-induced cardiac hypertrophy. 27 Thus, interdependence for vascular and cardiac hypertrophy is most likely. Although vascular EGFR-silenced mice develop cardiac hypertrophy and hypotension with aging, 22 this phenotype could be because of cardiac EGFR silencing because the sm22α-promoter also drives significant deletion of EGFR in cardiomyocytes. 22 Indeed, recent studies have reported a cardioprotective role for EGFR. 28, 29 However, partially contrasting findings were observed in mice on cardiac hypertrophy, contractility, and apoptosis under the conditions of chronic isoproterenol infusion with cotreatment of EGFR inhibitors, 28, 30 albeit using distinct inhibitors and administrative routes. Therefore, further research is needed to clarify the roles of cell type-specific EGFR transactivation induced by distinct G protein-coupled receptors in cardiac pathophysiology such as those using both cardiomyocyte and VSMC EGFR-deficient mice.
Although ER stress has been implicated in cardiovascular diseases, 14 limited information has been available about its role in hypertension and associated complications. It has been recently reported that ER stress inhibitors attenuate AngIIinduced aortic apoptotic and fibrotic responses in rats. 31 Our data further suggest a potential prevention of hypertensive cardiovascular remodeling (but not hypertension) by reducing ER stress through inhibition of the ADAM17/EGFR axis of AngII signal transduction. However, PBA treatment was reported to attenuate hypertension in AngII-infused mice. 19, 32 Brain-selective treatment of ER stress inhibitor, tauroursodeoxycholic acid, also attenuates AngII-induced hypertension in mice. 20 It is possible that the antihypertensive effect of PBA might be overridden in the present study because a higher concentration of AngII was infused. In addition, mechanical stretch of VSMCs, which is enhanced during hypertension, may lead to EGFR activation 33 and ER stress 34 in these cells. However, this may not be the case in our study because hypertension was unaltered with either treatment. It should also be noted that most of the remodeling assessments were not completely inhibited by erlotinib or PBA. As EGFR activation or ER stress was completely suppressed by the corresponding inhibitor, respectively, it is likely that there is a minor but still important signaling mechanism causing cardiovascular remodeling independently of the EGFR/ER stress cascade.
Inhibition of ADAM17 induction with EGFR inhibition or ER stress inhibition suggests the presence of a feed-forward ADAM17 signal amplification, which seems to involve transcriptional upregulation of ADAM17. Indeed, the ADAM17 promoter has functional ER stress responsible elements. 35 We have recently demonstrated that ADAM17 mRNA induction in aorta in response to AngII infusion was inhibited by erlotinib treatment. 36 Hypoxia-inducible factor-1α seems to mediate ADAM17 promoter activation by AngII, 37 and AngII is reported to activate hypoxia-inducible factor-1α through EGFR transactivation in VSMCs. 38 ER stress may also be involved in hypoxiainducible factor-1α activation as reported in the vascular endothelial growth factor promoter. 39 Thus, AngII induction of ADAM17 via EGFR activation may involve downstream signal crosstalk between hypoxia-inducible factor-1α and ER stress.
It has been reported that activation of vascular EGFR or ER stress causes endothelial cell dysfunction, 19, 21 which could be important to enhance vascular remodeling in response to AngII. Aldosterone antagonism also prevents AngIIdependent vascular and cardiac fibrosis. 40 Although the role of EGFR in aldosterone-induced cardiovascular remodeling remains controversial, 41 it will be interesting to test the causal role of ER stress in aldosterone-induced vascular remodeling in the future.
Perspectives
EGFR signal transduction seems to be essential for cardiovascular remodeling associated with ER/oxidative stress but not for hypertension in mice with AngII infusion. The signal seems to include a feed-forward mechanism involving vascular ADAM17 induction via ER stress acting on its gene promoter, which enhances EGFR ligand production and subsequent EGFR activation and vascular remodeling ( Figure  S4 ). ER stress also causes reactive oxygen species generation, enhancing EGFR activation. Additional research in this cascade is warranted to seek for alternative or additive treatments against hypertension and its complications. What Is New?
• Analyses of blood pressure and vascular pathology in the heart, kidney, and aorta with intervention established a role for epidermal growth factor receptor (EGFR) and endoplasmic reticulum stress in angiotensin II-induced pathological vascular remodeling independent of hypertension in mice.
• The concept of the feed-forward induction of vascular disintegrin and metalloproteinase domain 17 (ADAM17) to amplify the EGFR pathway and subsequent vascular remodeling was presented.
What Is Relevant?
• Results indicating prevention of vascular remodeling but not hypertension by erlotinib or 4-phenylbutyrate provide a foundation to seek a potential add-on therapy to current pressure-lowering treatments for hypertension.
• The vascular restricted EGFR signal transduction highlights the importance of vascular pathology for subsequent tissue dysfunction in hypertension.
Summary
In angiotensin II-infused mice, vascular hypertrophy and perivascular fibrosis were prevented by pharmacological inhibition of EGFR activity and endoplasmic reticulum stress. Angiotensin II infusion showed vascular ADAM17 induction, EGFR activation, and endoplasmic reticulum stress, which were attenuated by respective inhibitors. Cultured vascular cells were used to confirm the potential feed-forward mechanism of ADAM17 induction through transcriptional activation. Data were obtained from 4 mice in each group with 3 to 4 non-overlapping high power fields for each antibody.
Novelty and Significance

Cell Culture and Experiments
VSMCs were prepared from thoracic aorta of male Sprague-Dawley rats by the explant method as described previously 2 . VSMCs were subcultured in DMEM containing 10% fetal bovine serum, penicillin and streptomycin. Cells from passage 3 to 10 at 80~90% confluence were made quiescent by incubation with serum-free medium for 2-3 days.
To avoid any potential phenotypic alteration, VSMCs were renewed every 2-3 months and VSMCs from frozen stock were never used. The results were confirmed in at least 2 distinct cell preparations. Immunoblotting (IB) was performed as previously described 2 . Quiescent VSMCs grown on 6-well plates were stimulated with AngII (Sigma) for specified durations. The reaction was terminated by the replacement of medium with 100 µL of 1xSDS lysis buffer. 40 µL of the cell lysates were subjected to SDS-PAGE gel electrophoresis and electrophoretically transferred to a nitrocellulose membrane.
The membranes were then exposed to primary antibodies overnight at 4 °C. After incubation with the peroxidase linked secondary antibody for 1 h at room temperature, immunoreactive proteins were visualized using a chemiluminescence reaction kit.
ADAM17 promoter assay was performed as we have reported previously with a modification to replace the luciferase expression vector with an adenovirus encoding the luciferase cassette 3 for VSMC transduction. Recombinant adenoviral vector encoding mouse GRP78 cDNA 4 was obtained from Iowa Gene Vector Core. VSMCs were infected with adenovirus as reported previously 5 . Mean±SEM (n=8), *p<0.001 compared with saline infusion. BW: body weight; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate. Figure S1 . EGFR inhibitor Erlotinib attenuated ADAM17 induction and ER/oxidative stress induced by AngII in coronary arteries. Specific staining intensity at medial area in Figure 1F was quantified with subtraction of control IgG staining intensity of the corresponding area (n=4, means ± SEM), p<0.05 compared with control saline infusion. †p<0.05 compared with AngII infusion. Figure S4 . Potential feed-forward signaling mechanism by which AngII induces hypertensive vascular remodeling. Induction of ADAM17 expression by AngII via ER stress acting upon its gene promoter enhances EGFR ligand production and subsequent EGFR activation and vascular remodeling. ER stress also causes ROS generation, enhancing EGFR activation. 
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